AgingResearch.NewsJoin free

Cerevance

CompanyUnited States

Cerevance develops one asset, in phase 3 (solengepras in Parkinson's disease). Mostly small molecule acting on GPR6; based in the United States.

1
Asset
Furthest stage
Phase 3
0
Trials
0
Signals

Pipeline

1

  • solengepras

    GPR6 inverse agonist that modulates striatal motor pathways to reduce Parkinson’s motor fluctuations.

    Phase 3, Small molecule, GPR6, Parkinson's disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Similar companies6

Intelligence